555,953 Shares in Becton, Dickinson and Company $BDX Bought by Everett Harris & Co. CA

Key Points

• Everett Harris & Co. CA initiated a position in Becton, Dickinson and Company by purchasing 555,953 shares valued at approximately $84.1 million, representing about 0.20% of BDX and 1% of the firm’s portfolio.
• Analysts maintain a consensus “Hold” rating, with an average price target of $185.67; individual targets range from $170 to $210.
• BDX surpassed quarterly earnings and revenue estimates, reporting $3.23 in adjusted EPS and $4.98 billion in revenue, while declaring a $1.05 quarterly dividend yielding about 2.3% annually.

Everett Harris & Co. CA bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 555,953 shares of the medical instruments supplier's stock, valued at approximately $84,132,000. Becton, Dickinson and Company makes up approximately 1.0% of Everett Harris & Co. CA's investment portfolio, making the stock its 21st largest position. Everett Harris & Co. CA owned about 0.20% of Becton, Dickinson and Company at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth $26,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the first quarter worth $29,000. Finally, Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company in the fourth quarter valued at $29,000. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BDX shares. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Jefferies Financial Group restated a "buy" rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Barclays upped their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Finally, UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $185.67.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $183.16 on Friday. The firm has a market capitalization of $50.47 billion, a P/E ratio of 55.17, a price-to-earnings-growth ratio of 12.82 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm's fifty day moving average price is $157.84 and its two-hundred day moving average price is $161.70. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 over the last 90 days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source